MX2013005833A - Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. - Google Patents

Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.

Info

Publication number
MX2013005833A
MX2013005833A MX2013005833A MX2013005833A MX2013005833A MX 2013005833 A MX2013005833 A MX 2013005833A MX 2013005833 A MX2013005833 A MX 2013005833A MX 2013005833 A MX2013005833 A MX 2013005833A MX 2013005833 A MX2013005833 A MX 2013005833A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
casein kinase
pyridine compounds
fused pyridine
novel fused
Prior art date
Application number
MX2013005833A
Other languages
English (en)
Other versions
MX338551B (es
Inventor
Todd W Butler
Ramalakshmi Y Chandrasekaran
Scot R Mente
Chakrapani Subramanyam
Travis T Wagner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013005833A publication Critical patent/MX2013005833A/es
Publication of MX338551B publication Critical patent/MX338551B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Abstract

Se describen compuestos y sales de estos aceptables desde el punto de vista farmacéutico, en donde los compuestos tienen la estructura de la Fórmula I: (Ver Formula) y sales de estos aceptables desde el punto de vista farmacéutico, en donde X, Y, A, R4, n y R7 son como se definen en la memoria descriptiva. También se describen composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis e intermediarios correspondientes.
MX2013005833A 2010-12-20 2011-12-06 Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. MX338551B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
PCT/IB2011/055489 WO2012085721A1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013005833A true MX2013005833A (es) 2013-07-05
MX338551B MX338551B (es) 2016-04-20

Family

ID=45446116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005833A MX338551B (es) 2010-12-20 2011-12-06 Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.

Country Status (24)

Country Link
US (1) US8536164B2 (es)
EP (2) EP2654750B1 (es)
JP (2) JP5684923B2 (es)
KR (1) KR101590236B1 (es)
CN (1) CN103260622B (es)
AR (1) AR084412A1 (es)
AU (1) AU2011346733C1 (es)
CA (1) CA2819961C (es)
CY (2) CY1118772T1 (es)
DK (2) DK3181133T3 (es)
ES (2) ES2744099T3 (es)
HK (1) HK1188145A1 (es)
HR (2) HRP20170484T1 (es)
HU (2) HUE032405T2 (es)
IL (1) IL226948A (es)
LT (2) LT3181133T (es)
MX (1) MX338551B (es)
PL (2) PL3181133T3 (es)
PT (2) PT3181133T (es)
RS (2) RS55897B1 (es)
SG (1) SG190802A1 (es)
SI (2) SI3181133T1 (es)
WO (1) WO2012085721A1 (es)
ZA (1) ZA201303453B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2493876B1 (en) * 2009-10-28 2014-02-12 Pfizer Inc Imidazole derivatives as casein kinase inhibitors
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
CN104837844B (zh) * 2012-12-21 2017-08-29 百时美施贵宝公司 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
EP4126878A1 (en) * 2020-03-27 2023-02-08 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
WO2022058920A1 (en) * 2020-09-17 2022-03-24 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
CN116490503A (zh) * 2020-09-17 2023-07-25 詹森药业有限公司 酪蛋白激酶1δ调节剂
CN116888126A (zh) * 2020-12-15 2023-10-13 北京原基华毅生物科技有限公司 一种酪蛋白激酶抑制剂的化合物
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
EA003925B1 (ru) * 1997-05-22 2003-10-30 Дж.Д.Сирл Энд Ко ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ
AU2728201A (en) * 1999-12-21 2001-07-03 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
EA017278B9 (ru) 2005-06-22 2013-01-30 Кемосентрикс, Инк. Соединения азаиндазола и способы применения
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2493876B1 (en) * 2009-10-28 2014-02-12 Pfizer Inc Imidazole derivatives as casein kinase inhibitors

Also Published As

Publication number Publication date
LT2654750T (lt) 2017-05-10
CA2819961A1 (en) 2012-06-28
AU2011346733C1 (en) 2015-12-24
CN103260622B (zh) 2015-05-13
HRP20170484T1 (hr) 2017-06-02
CN103260622A (zh) 2013-08-21
CY1118772T1 (el) 2017-07-12
ZA201303453B (en) 2014-07-30
ES2623387T3 (es) 2017-07-11
JP5684923B2 (ja) 2015-03-18
SG190802A1 (en) 2013-07-31
EP2654750A1 (en) 2013-10-30
AU2011346733B2 (en) 2015-08-13
MX338551B (es) 2016-04-20
DK2654750T3 (en) 2017-05-01
PL2654750T3 (pl) 2017-07-31
KR20130121126A (ko) 2013-11-05
PL3181133T3 (pl) 2019-12-31
CA2819961C (en) 2015-08-18
AU2011346733A1 (en) 2013-07-18
JP2015107992A (ja) 2015-06-11
RS59098B1 (sr) 2019-09-30
SI3181133T1 (sl) 2019-10-30
US20120157440A1 (en) 2012-06-21
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
ES2744099T3 (es) 2020-02-21
DK3181133T3 (da) 2019-08-26
HUE047089T2 (hu) 2020-04-28
SI2654750T1 (sl) 2017-04-26
PT2654750T (pt) 2017-05-04
EP3181133B1 (en) 2019-07-24
LT3181133T (lt) 2019-09-25
EP2654750B1 (en) 2017-03-08
WO2012085721A1 (en) 2012-06-28
JP5876596B2 (ja) 2016-03-02
KR101590236B1 (ko) 2016-01-29
US8536164B2 (en) 2013-09-17
EP3181133A1 (en) 2017-06-21
CY1122062T1 (el) 2020-11-25
JP2014503544A (ja) 2014-02-13
AR084412A1 (es) 2013-05-15
RS55897B1 (sr) 2017-08-31
HK1188145A1 (en) 2014-04-25
PT3181133T (pt) 2019-09-16
IL226948A (en) 2017-04-30

Similar Documents

Publication Publication Date Title
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12015500376A1 (en) Novel bicyclic pyridinones
IN2012DN03182A (es)
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
MY149731A (en) Compounds
MY172924A (en) Neprilysin inhibitors
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
GB201209587D0 (en) Therapeutic compounds
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
GB201101517D0 (en) Receptor antagonists
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MY178583A (en) Hydantoin derivative
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
WO2011125006A3 (en) Sultam compounds
MX356499B (es) Derivados de heteroarilamida novedosos que tienen propiedades antiandrogénicas.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
MX2011012329A (es) Nuevas sales farmaceuticamente aceptables de 4-(1h-imidazol-4-ilme til)piridina y sus usos terapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration